How does Veligrotug actually work inside my body to help my thyroid eye disease?
Veligrotug is a monoclonal antibody that blocks the IGF-1 receptor on immune cells and eye tissue, stopping the inflammatory cascade that causes eye swelling, bulging, and double vision in thyroid eye disease. In the THRIVE Phase 3 trial, 67% of patients achieved ≥2 mm reduction in eye bulge (proptosis) compared to 33% on placebo [1].
In thyroid eye disease, your immune system mistakenly attacks the muscles and fat behind your eyes, causing them to swell and push your eyeballs forward. Veligrotug blocks a growth signal called IGF-1 receptor, which is the fuel that drives this immune attack. Think of it like turning off the ignition switch on the inflammation engine [1].
When you receive a Veligrotug injection, the antibody travels through your bloodstream and attaches to IGF-1 receptors on immune cells and eye tissue. This blocks the receptor from receiving growth signals, which stops the cells from multiplying and releasing inflammatory chemicals. Your eye swelling gradually decreases over 4–8 weeks as the inflammation quiets down [2].
Most patients need 3 induction injections (one every 3 weeks) followed by maintenance injections every 4 weeks for 4–6 months. Some patients see improvement within 2 weeks, while others take 8 weeks. If you don't see at least 2 mm of eye bulge reduction after 8 weeks, your eye doctor may recommend switching to a different treatment [1].
Ask your eye doctor: 'When should I expect to see my eyes start to feel less puffy, and what specific measurements will you use to track my progress?' Bring a photo of your eyes from before treatment to your follow-up visits so you can see the improvement yourself.